Top Tweets for #MSKACCESS
🚀 We are extremely proud to announce the launch of MSK-ACCESS® powered with SOPHiA DDM™! We want to warmly thank everyone who joined our launch event in Switzerland and contributed to make this insightful gathering a success!
#oncology #MSKACCESS #MSK #cancerresearch #AI
Happy to share our latest work in MSI-H/MMR-deficient lung cancers. Huge collaborative effort made possible through #MSKIMPACT #MSKACCESS profiling. Please check out our paper on the cover page of @JTOonline https://t.co/U2t4aOjAiF
Deeply appreciative of everyone who helped develop #MSKimpact, #MSKaccess, #MPath, @OncoKB, @cbioportal, and of the physicians, scientists, nurses, administrators, clinic staff, couriers & accessioners who deliver precision diagnostics day after day. @MSKPathology @MskccCMO
How 2 MSK-developed #cancer #genetictests - MSK-IMPACT® (which uses a tissue biopsy to identify the best treatment) & MSK-ACCESS® (a blood test to detect a patient's response to treatment) - have helped revolutionize the way cancer is treated worldwide: https://t.co/V4ml1fDJe9
Had a great time discussing biomarker testing and AI for lung cancer diagnosis! Multidisciplinary teamwork is so important! Thank you for the invite! @MSKPathology #MSKIMPACT #MSKFusion #MSKACCESS
Please check out our latest review on rare lung cancer subtypes! @MSKPathology #mskimpact #mskfusion #mskaccess
In a Review now published online, Guilherme Harada, Soo-Ryum Yang, @emilianoCocco2 and @alexdrilon discuss some molecular subtypes of #lungcancer that, despite occurring in <5% of patients with this cancer type, affect a considerable number of individuals https://t.co/ECSkUEaqZR
Amazing! Pls check out our pan-cancer study on RET fusion detection using FISH, DNA/RNA-NGS, IHC and ctDNA https://t.co/SmlXpyTsRY @CCR_AACR @JackieHechtman @alexdrilon @MLadanyi @DrEzraRosen @MSKPathology @MSK_DeptOfMed #MSKIMPACT #MSKFusion #MSKACCESS
💥🚨 MAJOR MILESTONE in #PRECISIONMEDCICINE Honored to share today👉FDA approved Selpercatinib in a tumor agnostic manner for RET fusion positive cancers
👉5th agnostic approval https://t.co/wTJsq05myq
MSI-H 2017, NTRK 2018, TMB-H 2020, BRAF V600 2022 https://t.co/3epaB4rfST
Congrats Sara! @saradinaps for presenting the NYS validation data for #mskaccess Heme, a liquid biopsy NGS-based assay that would benefit #lymphoma patients at #AACR2022. @MSKPathology @ARoseBrannon @RPtash 👏 ⭐️
.@saradinaps on “#MSKACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with #lymphoma,” which will allow for more info to be gathered about a tumor in a noninvasive way. #AACR22
#DNAsequencing #ngs #genomics @MSKCancerCenter: '.@saradinaps on “#MSKACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with #lymphoma,” which will allow for more …, see more https://t.co/3KhlfSdJL5
.@saradinaps on “#MSKACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with #lymphoma,” which will allow for more info to be gathered about a tumor in a noninvasive way. #AACR22
A simple blood draw can yield a wealth of lifesaving information. See how #MSKAccess, our in-house #LiquidBiopsy test, has allowed us to sequence thousands of tumors to help guide treatment decisions and detect recurrences earlier. #AACR22 https://t.co/ijq3fXkx18
One of the most exciting developments in cancer care has been the increased use of #LiquidBiopsies to analyze tumors. Read more about #MSKAccess and how simple blood draw can yield a wealth of lifesaving information. @MLadanyi @MFBerger1 @ahmetz https://t.co/kE8AGTwdwu
One of the most exciting developments in cancer care has been the increased use of #LiquidBiopsies to analyze tumors. Read more about #MSKAccess and how simple blood draw can yield a wealth of lifesaving information. @MLadanyi @MFBerger1 @ahmetz https://t.co/kE8AGTwdwu
Continued leadership Memorial Sloan Kettering and their #MSKAccess cfDNA test from treatment selection. This manuscript offers a perspective and adds data to the debate on how to address somatic v germline and clonal hematopoiesis in cfDNA https://t.co/51oQBGMRql
Finally out in @NatureComms, the validation and clinical experience of our plasma-based assay #MSKaccess
https://t.co/NKX57769Ei. Thank you, my wonderful colleagues for the journey and reviewer #2 for making us more resilient, one question at a time...
It was very satisfying to be part of this institutional effort to make a safer, less painful, and sometimes more informative method to profile patients' cancers. Thank you to everyone who put in tremendous work to bring #MSKaccess to life.
Finally out in @NatureComms, the validation and clinical experience of our plasma-based assay #MSKaccess
https://t.co/NKX57769Ei. Thank you, my wonderful colleagues for the journey and reviewer #2 for making us more resilient, one question at a time...
Finally out in @NatureComms, the validation and clinical experience of our plasma-based assay #MSKaccess
https://t.co/NKX57769Ei. Thank you, my wonderful colleagues for the journey and reviewer #2 for making us more resilient, one question at a time...
Almost exactly a year later, our manuscript on #MSKaccess is out in @NatureComms 🎉 Paper is here https://t.co/uGGtPQP32t, a short thread about it below.
Excited to share our new pre-print on a new plasma NGS assay for our patients: MSK-ACCESS (https://t.co/6aj1ZwMNVQ). Tissue based genomic testing is fine until obtaining the biopsy is not or the tissue material is not suitable for testing (8.8% our experience) 🧵
Wonderful tweetorial by @ahmetz. Our @biorxivpreprint summarizes the analytical validation of #MSKaccess and our clinical experience based on 681 cfDNA samples. We also highlight the importance of matched WBC sequencing in filtering out germline and CH variants (1/2).
As with every major project, this was a huge team effort between the clinical lab + innovation team + clinicians + bioinformaticians + software engineers + admin support and more. @ARoseBrannon , Gowtham, @DNA_tsui , @MFBerger1 and @RymaBenayed were indispensable
Congratulations to my friend and collaborator @DNA_tsui on this major accomplishment! We cannot wait to use #MSKAccess in the clinic to better care for our patients with #sarcoma @sloan_kettering
A realization of bench to bedside: Over 2 years from a concept to a test @MSKaccess cell-free DNA liquid biopsy test received NYSDOH approval today - look forward to transforming the way we care for our patients. Excellent team work @MFBerger1 @ahmetz @RymaBenayed @MLadanyi
Exciting news on our in house #liquidbiopsy panel #MSKAccess! Looking forward to the research projects that are coming down the pipeline very soon!
Big news about our #liquidbiopsy panel, MSK-ACCESS. Major thanks and kudos to a huge team! Early dev led by #CMO #InnovationLab, @houckloomis, @DNA_tsui. Clinical validation led by #RoseBrannon, @RymaBenayed, @ahmetz. So many others. Looking forward to launch, @MLadanyi! #ASCO19
Last Seen Hashtags on Sotwe
hornyasfuck
Seen from Pakistan
ميقا_حصريات
Seen from Turkey
裸舞
Seen from Malaysia
nolimit(***) filter:native_video
Seen from United States
finansalköle
Seen from Turkey
omnia
Seen from United Kingdom
MeenakshiChaudhary
Seen from India
OTD
Seen from United States
nolimit() or #momson
Seen from Austria
omeglelove
Seen from Australia
Most Popular Users
Elon Musk 
@elonmusk
241.1M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.4M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.1M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.3M followers
KATY PERRY
@katyperry
88.7M followers
Taylor Swift
@taylorswift13
82.6M followers
Lady Gaga
@ladygaga
74.1M followers
Virat Kohli
@imvkohli
71.5M followers
Kim Kardashian
@kimkardashian
70.3M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.5M followers
Neymar Jr
@neymarjr
64.4M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.8M followers
X
@x
60.8M followers